STRO
SUTRO BIOPHARMA, INC.
-0.13 (-0.83%)15.47USD144K成交股數257M市值–本益比(近四季)5.6股價營收比-84.6%營收年增(近四季)–下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 9.8M-43% | 14.5M-2% | 9.7M+14% | 63.7M+148% | 17.4M+34% | 14.8M-12% | 8.5M-18% | 25.7M+103% | 13.0M | 16.9M | 10.4M | 12.7M |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 31.7M | 36.6M | 39.9M | 38.3M | 51.6M | 71.0M | 62.1M | 62.0M | 56.9M | 45.7M | 41.6M | 39.4M |
| 銷售管理費用 | 7.8M | 7.6M | 8.7M | 10.3M | 13.3M | 9.0M | 14.3M | 12.4M | 12.7M | 15.3M | 15.0M | 15.5M |
| 營業利益 | −29.9M-56% | −29.7M-55% | −48.5M-29% | −3.3M-93% | −68.5M+21% | −65.3M+48% | −67.9M+47% | −48.7M+15% | −56.6M | −44.0M | −46.2M | −42.2M |
| 營業利益率 | -303.8% | -204.2% | -499.9% | -5.2% | -393.8% | -440.7% | -797.2% | -189.4% | -435.0% | -260.1% | -443.5% | -333.3% |
| 稅後淨利 | −38.5M-49% | −38.5M-47% | −56.9M+17% | −11.5M-76% | −76.0M+31% | −72.0M+46% | −48.8M+27% | −48.0M-4% | −58.2M | −49.3M | −38.5M | −50.1M |
| 淨利率 | -391.6% | -265.0% | -586.6% | -18.0% | -436.6% | -486.1% | -572.6% | -186.8% | -447.5% | -291.2% | -370.0% | -394.9% |
| 稀釋 EPS | -2.33-74% | -2.94-89% | -0.67+14% | -1.35+129% | -9.08+1439% | -27.63+3311% | -0.59-8% | -0.59-31% | -0.59 | -0.81 | -0.64 | -0.85 |
| 稀釋股數 | 16.6M | 13.1M | 84.9M | 8.5M | 8.4M | 7.7M | 82.0M | 81.2M | 61.5M | 60.6M | 60.3M | 58.7M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 54.3M | 73.7M | 65.9M | 64.0M | 106M | 190M | 175M | 90.8M | 65.2M | 81.8M | 235M | 62.5M |
| 應收帳款 | 5.8M | 12.5M | 3.9M | 8.0M | 13.6M | 8.6M | 6.7M | 7.0M | 31.3M | 16.6M | 10.0M | 9.9M |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 194M | 242M | 210M | 262M | 321M | 387M | 452M | 489M | 403M | 432M | 465M | 358M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 298M | 309M | 297M | 294M | 347M | 343M | 341M | 337M | 305M | 319M | 310M | 173M |
| 股東權益 | −103M | −66.9M | −87.3M | −32.1M | −25.8M | 44.6M | 111M | 152M | 98.0M | 112M | 155M | 185M |
| 負債比 | 153.1% | 127.6% | 141.6% | 112.2% | 108.0% | 88.5% | 75.4% | 68.9% | 75.7% | 74.0% | 66.7% | 48.2% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −42.3M | – | – | −67.9M+5% | – | – | – | −64.7M | – | – | −61.0M |
| 資本支出 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流 | – | – | – | – | – | – | – | – | – | – | – | – |
| 折舊攤銷 | – | 1.3M | – | – | 1.9M | – | – | – | 1.8M | – | – | 1.6M |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | – | – | – | – | – | – | – | – |
營收拆解
這家公司的 XBRL 沒有標分部、產品或地區營收。多半是單一業務,或只在 10-K 文字裡揭露。
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 102M | +65.2% | −191M | -186.4% | -22.49 | – |
| FY2024 | 62.0M | -59.6% | −227M | -365.9% | -29.40 | – |
| FY2023 | 154M | +126.8% | −107M | -69.6% | -1.78 | – |
| FY2022 | 67.8M | +9.5% | −119M | -175.9% | -2.35 | – |
| FY2021 | 61.9M | +44.8% | −106M | -170.6% | -2.29 | – |
| FY2020 | 42.7M | -0.0% | −32.1M | -75.2% | -0.99 | – |
| FY2019 | 42.7M | +11.2% | −119M | -278.9% | -2.43 | – |
| FY2018 | 38.4M | – | −35.3M | -91.9% | -6.13 | 11.1M |